**HNY Single System Formulary Alignment**

**Chapter 10 – Musculoskeletal**

[HNY Traffic Light Classification – Short Summary](https://sway.cloud.microsoft/Iwb2FkNHgtFwYfEN?ref=Link)

Changes to note - Right hand column – either aligned or change to North Yorkshire and York current formulary (NYY side) or change to Humber current formulary (Humber side)

| **BNF Section** | **Section Description** | **Medicine and form** | **NEW HNY APC RAG Alignment** | **Change** |
| --- | --- | --- | --- | --- |
|  |  | Ibuprofen solution for infusion | Red – specialist use only. Hospital only. | Addition to NYY side |
| 10.1.1 |  | Ibuprofen tablets (suspension if person cannot swallow tablets) | Green – 1st choice |  |
| Naproxen oral tablets | Green – 2nd choice  1st NSAID choice for gout. |  |
| Diclofenac sodium oral tablets  Diclofenac suppositories | Amber specialist recommendation  cardiovascular safety must be considered on individual basis. | Yes – change for NYY side to Amber SR – safety grounds |
| Diclofenac solution for injection | Red – specialist use only. Hospital only. |  |
| Meloxicam oral tablets | Green – after ibuprofen and naproxen | Addition for NYY side |
| Celecoxib oral; capsules  For OA, RA and AS | Amber specialist recommendation only after other NSAIDs have been tried. | Yes – change for NYY side to Amber SR – safety grounds |
| Celecoxib oral - for palliative care. | Move to palliative care section  Green as part of a palliative care pathway. |  |
| Etoricoxib for OA, RA and AS  Prescribing information updated to lower recommended dose of 60 mg daily for patients with rheumatoid arthritis or ankylosing spondylitis. | Amber specialist recommendation only after other NSAIDs have been tried. | Yes – change to Amber SR – safety grounds |
| Etoricoxib - for palliative care | Move to palliative care section - Green as part of a palliative care pathway. |  |
| Parecoxib injection | Red – specialist use only for palliative care only.  Move to palliative care section | Yes – addition to NYY side |
| Indometacin - capsules 25mg, 50mg; capsules SR 75mg;  Suppository 100mg  Use where alternative NSAIDs are not tolerated or effective | Green |  |
| Mefenamic acid tablets | Green |  |
| Ketoprofen | Do not prescribe – not routinely commissioned |  |
| 10.1.2.2 | Local corticosteroid injection | Methylprednisolone acetate injection | Green |  |
| Methylprednisolone acetate with lidocaine injection | Green |  |
|  | | |
| Hydrocortisone acetate injection | Green |  |
| Triamcinolone acetonide | triamcinolone acetonide suspension for injection vials, specifically Adcortyl (10mg/ml) and Kenalog (40mg/ml), are being discontinued. Stock is expected to be exhausted by early June 2025 |  |
| Triamcinolone hexacetonide inj | Red – specialist use only – hospital only. | Addition to Humber side |
| Dexamethasone sodium phosphate (joint injection): for in-patient or specialist team administration only.  Palliative care- raised intracranial pressure. | Red – specialist use only – hospital only. | Addition to NYY side |
| 10.1.3 | Drugs which suppress the rheumatic disease process | · Azathioprine oral | Amber Shared Care |  |
| · Penicillamine oral | Amber Shared Care |  |
| · Hydroxychloroquine oral | Amber Shared Care |  |
| · Mepacrine - for discoid lupus erythematosus (DLE) and for subacute cutaneous lupus erythematosus(SCLE): sub-section 10.1.3 antimalarials | Red – specialist use only – hospital only. |  |
| · Methotrexate oral tablets 2.5mg only | Amber Shared Care |  |
| · Methotrexate Inj | Amber Shared Care | Change for Humber to shared care |
| · Sulphasalazine oral | Amber Shared Care |  |
| · Ciclosporin oral | Amber Shared Care |  |
| · Leflunomide oral | Amber Shared Care |  |
| · Mycophenolate mofetil oral | Amber Shared Care |  |
| · Abatacept (Rheumatology) | Red – specialist use only |  |
| · Adalimumab | Red – specialist use only |  |
| · Anakinra | Red – specialist use only |  |
| · Apremilast | Red – specialist use only |  |
| · Baricitinib | Red – specialist use only |  |
| · Bimekizumab | Red – specialist use only |  |
| · Certolizumab Pegol | Red – specialist use only |  |
| · Cyclophosphamide | Red – specialist use only |  |
| · Etanercept (Benepali®; Embrel®) | Red – specialist use only |  |
| · Filgotinib | Red – specialist use only |  |
| · Golimumab | Red – specialist use only |  |
| · Guselkumab | Red – specialist use only |  |
| · Infliximab (Dermatology, Gastroenterology, Rheumatology) | Red – specialist use only |  |
| · Ixekizumab | Red – specialist use only |  |
| · Risankizumab | Red – specialist use only |  |
| · Rituximab (Rheumatology) | Red – specialist use only |  |
| · Sarilumab | Red – specialist use only |  |
| · Secukinumab | Red – specialist use only |  |
| · Tocilizumab (Rheumatology) | Red – specialist use only |  |
| · Tofacinitib | Red – specialist use only |  |
| · Upadacitinib | Red – specialist use only |  |
| · Ustekinumab | Red – specialist use only |  |
| · Voclosporin | Red – specialist use only |  |
| 10.1.4 | Gout and Cytotoxic induced hyperuricaemia | Allopurinol oral (prevention of gout) | Green 1st line |  |
| Colchicine oral (acute gout) | Green 1st line for gout |  |
| Prednisolone oral (acute gout) | Green 2nd line for gout |  |
| Febuxostat – (prevention of gout) in line with  <https://www.nice.org.uk/guidance/ng219> | Green |  |
| Probenecid | Red – specialist use only |  |
| Benzbromarone | Red – specialist use only |  |
| Glucosamine | Do not prescribe – not routinely commissioned |  |
| Canakinumab | Do not prescribe – not routinely commissioned |  |
| Cytotoxic induced hyperuricaemia | Rasburicase injection (Haematology/Oncology) (for in-patient or specialist team administration only) | Red – specialist use only |  |
| 10.2 | Drugs used in neuromuscular disorders | Risdiplam (Evrysdi®) | Red - Restricted, oral solution for treating Spinal Muscular Dystrophy- only commissioned by an appropriate service.  Tertiary centre only. |  |
| Nusinersen | Red - only commissioned by an appropriate service.  Tertiary centre only. |  |
| Ataluren | Red - only commissioned by an appropriate service.  Tertiary centre only. |  |
| Pyridostigmine Bromide oral - Myasthenia gravis | Amber specialist recommendation |  |
| Efgartigimod alfa - as per NHSE guidance: Specialised Commissioning: Subject to an Early Access to Medicines Scheme, for the treatment of adult patients with anti-acetylcholine receptor (AChR) antibody seropositive generalised myasthenia gravis (gMG), including patients with refractory gMG who have failed, not tolerated or are ineligible for licensed treatment. Please note that only Sheffield Teaching Hospitals NHS Foundation Trust is commissioned to provide this service within Yorkshire and Humber. | Red - only commissioned by an appropriate service.  Tertiary centre only. |  |
| Onasemnogene abeparvovec - only commissioned by an appropriate service: Approved for use in line with NICE guidance. NICE HST24 : Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophy Patients to be referred to a specialist centre - the following providers are commissioned to provide this service within Yorkshire and Humber: Sheffield Children’s NHS Foundation Trust | Red - only commissioned by an appropriate service.  Tertiary centre only. |  |
| 3, 4-Diaminopyridine - NHSE: Myasthenia gravis/LEMS (for in-patient or specialist team administration only) | Red - only commissioned by an appropriate service.  NHSE |  |
| Amifampridine - Not routinely commissioned by NHS England for the treatment of Eaton-Lambert Myasthenic syndrome (See NHSE policy statement D4/PS/a) | Do not prescribe - Not routinely commissioned |  |
| Fampridine | Do not prescribe - Not routinely commissioned |  |
| 10.2.2 | Skeletal muscle relaxants | Diazepam oral | Green |  |
| Dantrolene Sodium capsules | Amber specialist recommendation |  |
| Mexiletine capsules (Namuscla®)Mexiletine hydrochloride 200mg = 167mg mexiletine -NHSE commissioned.Local specialist centres include :**Hull University Teaching Hospital (adults)**Leeds Teaching Hospitals (adults and children)Sheffield Children’s Hospital (children)Sheffield Teaching Hospitals (children and adults) | Red – NHSE commissioned |  |
| Cannabis extract (Sativex®) - Adjunct in moderate to severe spasticity in multiple sclerosis (specialist use only) | Red – specialist use only | Change to red for NYY |
| Tizanidine oral - Spasticity associated with multiple sclerosis or spinal cord injury or disease | Amber specialist recommendation |  |
| Baclofen oral | Green |  |
| Baclofen injection | Red – specialist use only | Addition to NYY |
| Methocarbamol (less suitable for prescribing) | Do not prescribe - Not routinely commissioned |  |
| 10.2.2 | Nocturnal leg cramps | Advice (e.g. passive stretching exercises) - link to CKS |  |  |
| Quinine sulfate oral- not recommended for routine treatment and should not be used unless cramps cause regular disruption to sleep –see CKS  <https://cks.nice.org.uk/topics/leg-cramps/management/management/> | Green |  |
| 10.3 | Treatment of soft-tissue disorders and topical pain relief | Actipatch® | Do not prescribe - Not routinely commissioned |  |
| 10.3.1 | Enzymes | Hyaluronidase | Red – specialist use only |  |
| 10.3.2 | Rubefacients and other topical antirheumatics: | Ibuprofen gel 5% - for OA only  OTC treatment | Green. Suggest OTC.  1st line topical NSAID |  |
| Ibuprofen gel 10% non-formulary on cost grounds | Do not prescribe - Not routinely commissioned |  |
| Diclofenac 1.16% gel - for OA only  OTC treatment | Green |  |
| Piroxicam gel  OTC treatment | Green |  |
| Capsaicin cream – OTC treatment  **0.075% (Axsain)** – Used for **post-herpetic neuralgia** and **diabetic neuropathy**. Only for people with localised neuropathic pain who wish to avoid, or cannot tolerate, oral treatments  **0.025% (Zacin)** – Used for **osteoarthritis pain relief**. | Green | Currently unavailable until June 2026 |